These synthetic compounds effectively reduced mHTT levels in fibroblasts from HD patients, suggesting a novel therapeutic approach that targets the underlying molecular pathology of HD.536 Besides, mHTT can be degraded through autophagy by associating with autophagosomal protein LC3.249,537 Several mHTT-LC3 linker compounds (ATTECs) that facilitate allele-selective degradation of mHTT have been identified.249 These compounds specifically target mHTT for degradation through autophagy, improving HD symptoms in fly and mouse models. This evidence concerns the gene MAP1LC3A and Huntington disease.